Study S000377

Open-label, Double-arm, Controlled, Randomized, Multicentre Clinical Trial to Evaluate the Impact of Pharmacogenetic-guided Treatment in Patients With Insufficiently Controlled Type 2 Diabetes.

ClinicalTrials.gov record

Registration

Registration: NCT06851962
Acronym: EPHIC-DIA2
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: SINGLE
Status: COMPLETED
Enrollment: 92
Start: 2025-05-26
Primary completion: 2026-06-30
Lead sponsor: Fundación para la Investigación del Hospital Clínico de Valencia
Conditions: Diabetes Mellitus Type 2
Interventions: DRUG:Metformin; DRUG:Dulaglutide; DRUG:Semaglutide 1.0 mg; DRUG:Empagliflozin (BI 10773); DRUG:Canagliflozin; DRUG:Dapagliflozin; DRUG:pioglitazone; DRUG:Sitagliptin; DRUG:Vildagliptin (Galvus); DRUG:linagliptin
Results posted: FALSE
Secondary identifiers: CTIS:2025-520686-46-00; NIH:2025

Registered primary outcomes

Comparison of HbA1c ≤7% goal at Week 24 between Pharmacogenetic-Guided and Standard Treatment in Type 2 Diabetes [From baseline to the end of treatment at 24 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.